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dependent actions of insulin-like growth factor I
on neurons
Carolina Franco, Silvia Fernández and Ignacio Torres-Alemán*Abstract
Background: Friedreich´s ataxia (FRDA) is a neurodegenerative disease caused by deficiency of the mitochondrial
iron chaperone frataxin (Fxn). FRDA has no cure, but disease-modifying strategies to increase frataxin are under
study. Because insulin-like growth factor I (IGF-I) has therapeutic effects in various types of cerebellar ataxia and
exerts protective actions on mitochondrial function, we explored the potential Fxn-stimulating activity of this
growth factor on brain cells.
Results: IGF-I normalized frataxin levels in frataxin-deficient neurons and astrocytes through its canonical Akt/mTOR
signaling pathway. IGF-I also stimulated frataxin in normal astrocytes but not in normal neurons, whereas IGF-I
stimulated the Akt/mTOR pathway in both types of cells. This cell context-dependent action of IGF-I on neurons
suggested that the intrinsic regulation of Fxn in neurons is different than in astrocytes. Indeed, neurons express
much higher levels of frataxin and are much more sensitive to Fxn deficiency than astrocytes; i.e.: only neurons die
in the absence of frataxin. In addition, the half-life of frataxin is shorter in neurons than in astrocytes, while after
blockade of the proteasome only neurons responded to IGF-I with an increase in frataxin levels. We also explore a
potential therapeutic utility of IGF-I in FRDA-like transgenic mice (YG8R mice) and found that treatment with IGF-I
normalized motor coordination in these moderately ataxic mice.
Conclusion: Exposure to IGF-I unveiled a cell-specific regulation of frataxin in neurons as compared to astrocytes.
Collectively, these results indicate that IGF-I exerts cell-context neuroprotection in frataxin deficiency that maybe
therapeutically effective.
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Insulin-like growth factor I (IGF-I) is an abundant circu-
lating neuroprotective hormone, also synthesized in the
brain, that shows a wide variety of actions on brain cells
[1]. IGF-I treatment is beneficial for different brain dis-
eases, including various types of cerebellar ataxia in ani-
mal models [2-6] and human patients [7]. Whereas
general protective actions of IGF-I in the brain are well
documented, disease-specific actions of IGF-I, if any, are
not well established yet. There are several neurodegen-
erative conditions where IGF-I dysfunction is probable.
For example, there is evidence of specific disturbances in
IGF-I signaling in spinocerebellar ataxia 1 and 7 [8].* Correspondence: torres@cajal.csic.es
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© 2012 Franco et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orTwo other ataxic diseases with different etiology and
pathology, ataxia telangectasia and Friedreich´s ataxia
(FRDA), may also show disturbed IGF-I function. Both
types of ataxia show cumulative DNA damage. In the
case of ataxia telangectasia this is due to impaired DNA
repair, [9] while in FRDA excess oxidative stress appears
as the main culprit [10]. In turn, DNA damage is known
to reduce IGF-I activity [11]. At any rate, these two types
of ataxia present insulin resistance [12-14], a condition
often associated to IGF-I dysfunction [15].
In the present work we focused on a possible relation-
ship of IGF-I to FRDA, the main type of human inher-
ited ataxia. FRDA is associated to mitochondrial
dysfunction due to reduced frataxin levels, a mitochon-
drial iron chaperone involved in the metabolism of Fe-S
clusters [10]. Although we previously postulated thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.molecularneurodegeneration.com/content/7/1/51IGF-I administration may exert a beneficial effect in all
types of ataxia through its wide neuroprotective activ-
ities [16], in the case of FRDA a disease-modifying effect
of IGF-I may be envisaged if it improves frataxin func-
tion by modulating mitochondrial activity. The latter is
theoretically supported by the fact that brain mitochon-
dria are targeted by IGF-I [17] and that IGF-I enhances
mitochondrial activity [18,19]. The present work indi-
cates that IGF-I stimulates frataxin levels in a cell-
context fashion and is able to restore motor function in
a mouse model of FRDA with moderate ataxia.
Results
IGF-I modulates frataxin in a cell-context fashion
In FRDA patients, frataxin deficiency affects all cells in
the body although the disease manifests mostly as a
neurological illness. Hence, we determined possible
effects of IGF-I on frataxin-deficient neurons andC
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Figure 1 IGF-I stimulates frataxin in a cell-context fashion. A, Treatmen
deficient (right) but not in normal neurons (left). B, IGF-I stimulated frataxin
levels of reactive oxygen species (ROS) in frataxin-deficient astrocytes (uppe
content in cardiomyocytes. E, Levels of SOD2 are increased by IGF-I in wild
Western blots were performed to measure the levels of frataxin, SOD2 and
blots are shown; the upper blots correspond to frataxin (A, B, D), SOD2 (E)
experiments); *p<0.05; **p<0.01; ***p<0.001.astrocytes, the two most abundant cell types in the
brain. Both neurons and astrocytes made deficient in fra-
taxin after viral-mediated transduction of frataxin
shRNA showed recovered frataxin levels after 24 hours
of treatment with IGF-I (Figure 1A,B). An unspecific ef-
fect of IGF-I on RNA interference was ruled out using
calcineurin siRNA in astrocytes. In this case IGF-I did
not affect the siRNA-induced calcineurin decrease (not
shown). IGF-I also normalized reactive oxygen species
(ROS) levels in frataxin-deficient astrocytes or neurons
(Figure 1C). Notably, while IGF-I did not raise frataxin
levels in normal cerebellar (Figure 1A, righ panel) or
dorsal root ganglia neurons (not shown), it stimulated
frataxin in normal astrocytes (Figure 1B, right panel). To
ascertain whether IGF-I raises frataxin in other normal
cells, we determined its effects on cardiomyocytes, an-
other cell type affected in FRDA patients. As shown in
Figure 1D, IGF-I significantly increased levels of frataxinE
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aconitase, and protein load normalized against β-actin. Representative
or aconitase (F) and the lower blots to β-actin (n=3-6, independent
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http://www.molecularneurodegeneration.com/content/7/1/51in cardiomyocites. Finally, we determined whether IGF-I
specifically affects frataxin or other mitochondrial pro-
teins are also affected by this growth factor. As shown in
Figure 1E, IGF-I increased SOD2, another mitochondrial
protein with antioxidant activity. However, another
mitochondrial protein such as aconitase, involved in oxi-
dative metabolism, was not altered by IGF-I (Figure 1F).
While ablation of frataxin in mice is lethal [20], we
wanted to determine whether the survival of neurons
and astrocytes is also fully dependant on frataxin and
whether IGF-I exerts any protective effect in frataxin-
deleted cells. We ablated Fxn by expressing GFP-tagged
Cre recombinase in Fxn gene-floxed neurons and astro-
cytes. IGF-I could not rescue neurons because in the
absence of Fxn they died very rapidly (within less than
48 hours) even though only ≤40% of the neurons were
transfected with Cre (GFP+). Therefore, a non-cell
autonomous toxic effect appears to kill the rest of the
neurons with normal levels of frataxin. Conversely, in
Fxn-floxed astrocytes, expression of Cre led to aCrerecombinase
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Figure 2 Beneficial actions of IGF-I under severe frataxin deficiency. A
levels along time. Representative blot and quantification graphs of frataxin
astrocytes with 100nM IGF-I for 24 hours increased frataxin levels. Represen
cultures were normalized by IGF-I. D, Disturbed mitochondrial activity due
normalization of MTT levels. E, Astrocytes promote survival of frataxin-defic
hours. GFP+ (frataxin-deleted)-neurons were counted (n=4-5, independentpronounced decrease in frataxin levels as expected
(Figure 2A), but the cells remained alive and levels of
frataxin increased in response to IGF-I (Figure 2B).
Thus, a clear difference exists between astrocytes and
neurons in respect to their resilience to the lack of fra-
taxin. Further, as Cre-mediated ablation of floxed genes
is irreversible, IGF-I must increase frataxin only in non-
deleted cells, as already seen in non-transfected wild
type astrocytes (Figure 1B). As seen in Fxn shRNA-
transfected astrocytes (Figure 1C), IGF-I also normalized
ROS levels in Cre-deleted, Fxn-floxed astrocyte cultures
(Figure 2C). Furthermore, astrocyte metabolism mea-
sured with the MTT assay, a marker of mitochondrial
activity [21], was also normalized by IGF-I under these
conditions (Figure 2D). Again, these results suggest a
non-cell autonomous effect of frataxin. In this case, fra-
taxin was raised by IGF-I only in intact astrocytes, but
protected those without frataxin as well. Because astro-
cytes are important contributors to neuronal health we
then determined whether protection of astrocytes byB
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http://www.molecularneurodegeneration.com/content/7/1/51IGF-I could impact on neurons. We treated with IGF-I
Cre-transfected (GFP+), Fxn-floxed neurons (unable to
survive when cultured alone) co-cultured with wild type
astrocytes. The mere presence of astrocytes allowed neu-
rons without frataxin (GFP+) to survive, and treatment
with IGF-I modestly, but significantly increased their
number after 24 hours in co-culture (Figure 2E).
We then determined whether the neuroprotective effects
exerted by IGF-I in vitro could translate into a therapeutic
action. First, we analyzed whether IGF-I is active in human
cells. We used human astrocytes because murine astro-
cytes readily responded to IGF-I. Indeed, human astrocytes
showed increased Fxn levels after treatment with IGF-I
(Figure 3A). Next, we used a mouse model of FRDA to de-
termine the in vivo potential of IGF-I. Albeit with the usual
limitations of animal models, YG8R mice bearing the
human mutation in a null mouse frataxin background are
currently the model that most closely resembles the mo-
lecular basis of human FRDA [22]. All available mouse
models of FRDA show either a severe ataxic phenotype
and die soon after birth, or a modest degree of motor inco-
ordination, which is the case of YG8R mice. We treated
YG8R mice with sc IGF-I (50 μg/kg/day, Alzet minipumps)
for 1 month and determined motor coordination in the
rota-rod test. As shown in Figure 3B, IGF-I restored rota-
rod performance to control levels (p<0.01 vs untreated
YG8R mice). However, brain frataxin levels were not chan-
ged by IGF-I treatment (not shown). Collectively these data
support a therapeutic action of IGF-I in FRDA.
IGF-I modulates frataxin through a PI3K/Akt/mTOR
pathway
We next analyzed intracellular pathways underlying
the stimulatory actions of IGF-I. We first determinedBA
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Figure 3 Therapeutic utility of IGF-I. A, IGF-I (100 nM) treatment for 24 h
experiments). B, One month of treatment of YG8R mice (4–6 months-old) w
normalization of motor coordination in the rota-rod (F=10.1; n= 8–30). Nowhether IGF-I stimulates frataxin expression by inhi-
biting mRNA transcription with actinomycin D. In the
absence of mRNA synthesis, the stimulatory action of
IGF-I on frataxin levels in astrocytes was blocked
(Figure 4A). Using qPCR we confirmed that synthesis
of Fxn mRNA is increased by IGF-I in astrocytes
(Figure 4B). Accordingly, inhibition of protein transla-
tion with cycloheximide also abrogated the stimulatory
action of IGF-I on astrocytes (Figure 4C). Next, among
canonical pathways stimulated by IGF-I we found that
the PI3K/Akt/mTOR pathway is involved. Inhibition of
Akt activation with the PI3kinase inhibitor Ly294002
or of mTOR with rapamycin blocked the stimulatory
action of IGF-I (Figure 4D, E). In addition, levels of
phosphorylated mTOR, an indirect measurement of
its activity status, were also increased after IGF-I
(Figure 4F). Blockade of other kinases downstream of
the IGF-I receptor such as PKC did not modify the
increase in frataxin after IGF-I treatment (not shown).
Mechanisms underlying cell-context effects of IGF-I on
neurons
We then analyzed mechanisms underlying cell-context
actions of IGF-I on neurons. We first determined whether
mTOR is also involved in the stimulatory effect of IGF-I
on frataxin -deficient astrocytes and neurons. Indeed,
rapamycin blocked the stimulatory effect of IGF-I on
shRNA-transfected astrocytes (Figure 5A), and neurons
(Figure 5B). Next, we found that in normal neurons IGF-I
also stimulated mTOR phosphorylation (Figure 5C), even
though frataxin levels remain unchanged (Figure 1A).
Thus, activation of mTOR by IGF-I is necessary but not
sufficient to increase frataxin levels in neurons. We then
explored potential differences between astrocytes and1 2 3 4
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Figure 4 IGF-I stimulates frataxin in astrocytes through the PI3K/Akt/mTor pathway. A, Inhibition of mRNA transcription with actinomycin
D (ActD, 2 μg/ml) eliminated the stimulatory effect of IGF-I on frataxin levels. B, IGF-I significantly stimulates frataxin mRNA 6 hours after its
addition to astrocyte cultures returning to basal levels at 24 hours post-addition. C, Inhibition of protein synthesis with cycloheximide (Chx,
1 μg/ml) blocked the stimulatory effects of IGF-I on Fxn levels in astrocytes. D, Inhibition of PI3 kinase with 100 μM of Ly294002 inhibited the
stimulatory action of IGF-I on frataxin levels. E, Similarly, inhibition of mTor with rapamycin (100nM) also blocked the positive effect of IGF-I. F,
IGF-I stimulates phosphorylation of mTOR (pmTOR). Representative blot are shown; the upper blots correspond to frataxin and the lower blots to
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http://www.molecularneurodegeneration.com/content/7/1/51neurons in an attempt to understand the lack of effect of
IGF-I on normal neurons. We found that under basal con-
ditions the levels of frataxin mRNA and protein are very
high in neurons as compared to astrocytes (Figure 6A,B).
In addition, the half-life of frataxin in neurons was signifi-
cantly shorter than in astrocytes (Figure 6C). After inhib-
ition of protein synthesis with cycloheximide, levels of
frataxin dropped significantly faster in neurons (time effect
by ANOVA: F=5.32, p<0.05). As these results indicate that
frataxin degradation is faster in neurons than in astrocytes,
we inhibited proteasome activity with MG132 in these
two types of cells because frataxin has been shown to bedegraded through the proteasome [23]. Under these con-
ditions IGF-I was able to stimulate Fxn levels in wild type
neurons but not in astrocytes (Figure 6D). IGF-I also
increased Fxn in neurons treated with lactacystin, another
proteasome inhibitor, albeit more modestly (not shown).
Discussion
Our results suggest that IGF-I exerts cell context-
dependent stimulatory effects on Frataxin levels in neu-
rons. Thus, IGF-I stimulated frataxin in cerebellar neurons
only under frataxin deficiency or proteasome inhibition,
that is, only under conditions stressful to the cell but not
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Figure 5 IGF-I acts through mTOR in frataxin-deficient cells and normal neurons. IGF-I stimulates frataxin in a rapamycin (100nM) sensitive
way in frataxin-deficient astrocytes (A) and neurons (B). C, IGF-I increases phosphorylation of mTOR in neuronal cultures. Representative blot are
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Franco et al. Molecular Neurodegeneration 2012, 7:51 Page 6 of 10
http://www.molecularneurodegeneration.com/content/7/1/51under normal conditions. However, IGF-I stimulated the
mTOR pathway both in normal and in frataxin-deficient
neurons, regardless of its ultimate effects on frataxin
levels; i.e.: the mechanism of action of IGF-I is essentially
the same in neurons and astrocytes. Hence, it seems that
under normal conditions, IGF-I stimulates frataxin in neu-
rons, but this stimulatory action is masked by a parallel in-
crease in its degradation. Two observations support this
notion. First, basal expression of frataxin in neurons is
higher than in astrocytes. Probably this reflects a greater
dependency of neurons on this mitochondrial chaperone;
i.e.: neurons, but not astrocytes, die in the absence of fra-
taxin. At the same time, the half-life of frataxin is much
shorter in neurons than in astrocytes. This suggests that
proteasome degradation (frataxin has been shown to be
degraded through the proteasome [23]), is more active in
neurons than in astrocytes. Whether this is specific for
frataxin or merely reflects an overall greater proteasome
activity in neurons will require further study. Collectively,
these data suggest that under basal conditions, frataxin
levels in neurons are tightly regulated within a narrower
threshold than in astrocytes (and probably other cell
types). This is achieved by a balance between higher ex-
pression and continued degradation. When this balance is
disrupted, such as by RNA interference or proteasome in-
hibition, the stimulatory actions of IGF-I are unmasked
and neurons “become” responsive to IGF-I. This interpret-
ation predicts that frataxin promoter activity in neurons
will be higher than in other cell types, and that frataxin
levels in neurons are controlled by a proteasome-sensitive
mechanism, pointing to potential new pathways to explore
for therapeutical purposes. Whether this regulatory bal-
ance is present in other neuronal types, such as dorsal
root ganglia neurons, the primary target of FRDApathology, remains to be explored. As IGF-I also modu-
lated other mitochondrial proteins such as SOD2 (but not
aconitase), the action of IGF-I on frataxin may actually
reflect a broader mito-protective effect of this pleiotropic
neuroprotective factor.
The combined neuroprotective actions of IGF-I on neu-
rons and astrocytes open the possibility of combat neuro-
degeneration by enhancing frataxin levels in deficient cells
together with potentiation of the neuroprotective proper-
ties of astrocytes. The therapeutic potential of IGF-I is
reinforced by the positive effects exerted by IGF-I on fra-
taxin in cardiomyocytes, as cardiopathy is frequently
present in FRDA patients, and in human astrocytes, indi-
cating that findings using murine models may be trans-
lated into clinical practice. The fact that IGF-I protects
neurons from frataxin deficiency in a non-cell autono-
mous fashion also provides new potential targets for ther-
apy by exploring the underlying mechanisms. For
instance, IGF-I may promote the release of cytoprotective
factors by astrocytes that can rescue both astrocytes and
neurons from the absence of frataxin. This possibility is
currently under investigation.
Our initial in vivo study indicates that the neuroprotec-
tion exerted by IGF-I in vitro may be of therapeutical
consequence. Indeed, treatment with IGF-I of moderately
ataxic FRDA-like mice (YG8R mice) normalized their
motor coordination even though brain frataxin levels
remained unchanged. The latter is at odds with our
in vitro observation that IGF-I stimulates frataxin in cul-
tured cells. One possibility is that IGF-I cannot stimulate
frataxin in mice bearing the mutated frataxin gene
because the triplet repeat interferes with its actions on fra-
taxin synthesis. Alternatively, and less likely because the
YG8R mice bears the whole promoter region of the
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http://www.molecularneurodegeneration.com/content/7/1/51frataxin gene, IGF-I may not increase frataxin because
the transgene construction lacks the IGF-I-sensitive
regulatory region in the frataxin promoter. Direct
analysis on human cells from FRDA patients will answer
these possibilities. Other possibilities are that the pro-
tective effects of IGF-I, as seen in vitro, involve not only
a stimulatory effect on frataxin but also other neuropro-
tective processes that are sufficient to ameliorate the
modest functional deficit of YG8R mice. Another possi-
bility is that we cannot detect changes in frataxin levels
in YG8R mice treated with IGF-I because of lack of
sensitivity of our western blot, as measuring changes in
frataxin levels in the brain of YG8R mice is not straight-
forward [22].Although we cannot determine whether IGF-I will be
effective in reverting more severe ataxia, as no effective
treatments are available yet for this disease, and prelimin-
ary studies show beneficial effects of IGF-I in spinocere-
bellar ataxic patients [7], these results encourage its use in
FRDA patients as well. In fact, recent preliminary studies
in FRDA patients treated with IGF-I for 1 year show a
clear beneficial effect of this neurotrophic factor on
disease progression (J Arpa, personal communication).
Conclusions
These observations indicate that IGF-I exerts cell-specific
and context-dependent actions on neurons reinforcing the
notion that this growth factor may serve as a therapeutic
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http://www.molecularneurodegeneration.com/content/7/1/51agent by addressing emerging properties of the diseased
brain not present under healthy conditions [1].
Methods
Materials
Human IGF-I was purchased from ProSpec-Tany. The
protein synthesis inhibitor cycloheximide, the protea-
some inhibitorMG-132 (carbobenzoxy-L-leucyl-L-leucyl-
L-leucinal) and the phosphatidylinositol 3-phosphate
inhibitor (LY294002) were from Calbiochem. The mTOR
inhibitor rapamycin and the mRNA transcription inhibitor
actinomycin D were from Sigma-Aldrich. Primary anti-
bodies included anti-frataxin (H-155, 1:1000; Santa Cruz
Biotechnology), PGC-1 (1:1000; Santa Cruz Biotechno-
logy), Cre Recombinase (1:10000; Novogen), phospho-
mTOR (1:2000, Cell Signaling), mTOR (1:2000, Cell
Signaling), SOD2 (1:4000, Enzo Life Sci.), and β-actin
(1:100000; Sigma). Secondary antibodies were goat anti-
rabbit (1:10000) or mouse HRP-coupled (1:10000) both
from Bio-Rad.
Animals
Conditional FRDA mouse mutants of both sexes in
which exon 4 of frataxin is loxP-flanked (a kind gift of
Michel Koenig, Strasbourg University) congenic (> 10
generations) with C57Bl6 mice, and wild type mice of
the same strain were used. Multiplex PCR for mouse
genotyping included a common forward primer (P3,
5'−CTG TTT ACC ATG GCT GAG ATC TC−3') and
two reverse primers specific for the wild-type (P4,
5'−CCA AGG ATA TAA CAG ACA CCA TT−3') and
mutant (P2, 5’-CGC CTC CCC TAC CCG GTA GAA
TTC-3’) alleles. Compound FRDA mutants known as
YG8R mice [22] were obtained from Jackson Labs (Jax)
and bred according to its guidelines. The YG8R mouse is
currently considered the best animal model of FRDA as
it bears human mutated frataxin without endogenous
murine frataxin. Thus, at the molecular level this mouse
mimics the disease. However, as is usually the case in
transgenic mice, the phenotype only partially resembles
the human condition. YG8R mice show very modest
ataxia, the neurological hallmark of FRDA. Neuropathol-
ogy findings, as originally described by the authors [22]
are similar to those in human patients but less pro-
nounced. Mice were genotyped by PCR following Jax
protocols. Even though recent findings indicate that only
female YG8R mice show ataxia we used both males and
females (42% males) for these studies as breeding of
these mice require large amounts of animals to be pro-
duced and in our hands both sexes performed similarly
in the rota-rod test. The same gender proportion was
kept in control mice. All mice had access to food and
water ad libitum, were kept under 12:12 hour light/dark
conditions and handled according to institutionallyapproved procedures. YG8R mice treated with subcuta-
neous IGF-I using Alzet minipumps for 1 month had
human IGF-I levels in blood of 22.1 ±1.26 ng/ml
(human-specific ELISA from R&D, see [24]). Control
C57BL6 mice had undetectable levels
Cell cultures and transfections
Astroglial cultures with >95% GFAP-positive cells were
prepared as described [25]. Postnatal (day 3–4) brains
were dissected and immersed in ice-cold Hank’s balance
salt solution (Invitrogen). Cortex and hippocampus were
removed and mechanically dissociated. The resulting cell
suspension was centrifuged and plated in DMEM/F-12
(Invitrogen) with 10% fetal bovine serum (Invitrogen)
and 100mg/ml of antibiotic-antimycotic solution
(Sigma). After 15–20 days, astrocytes were re-plated at
1,2 × 105 cells/well. Pure cerebellar granule neurons
from postnatal mouse cerebellum (>99% β3-tubulin+
cells) were obtained as previously described [26]. Briefly,
P7 brains were dissected and immersed in ice-cold
Hank’s balance salt solution (Invitrogen). Cerebella were
removed and first dissociated mechanically, and then
enzimatically digested with papain solution (Worthing-
ton). Finally, neurons were plated in wells covered with
poly-L-lysine in medium with Neurobasal plus B27
(Invitrogen), glutamine, and 25 mM KCl at 4.5 × 105
cells/well. Cardiomyocyte cultures from the cardiac ven-
tricles of neonate mice were prepared as described [27].
In brief, excised hearts were separated into ventricular
and atrial tissues, and the ventricles were dissociated by
serial enzymatic digestion (5 digestions of 10 minutes
each) with 24 mg of collagenase type II (GIBCO) and 50
μg of DNAse (Sigma) in 50 ml of HBSS, using a shaker
at 37°C. Myocytes and non-myocytes were separated by
pre-plating for 30 minutes onto 10 cm2 plates in
medium containing 4:1 DMEM high glucose: M199
(GIBCO), 10% horse serum, 5% FCS, and 100 mg/ml
antibiotic-antimycotic.
Frataxin deficiency in neurons and astrocytes was eli-
cited following two different systems. First, we used viral
transduction using a three-plasmid system as described
previously (Dull et al., 1998). The co-transfection system
consisted of MissionW shRNA (Sigma-Aldrich), the pack-
aging construct (pCMVΔR-8.74) and the vesicular sto-
matitis virus G-protein envelope (pMD2.VSV.G). The
MissionW shRNAs were: turbo GFP (SHC0003V), non-
target shRNA (SHC002) or frataxin shRNA (NM_000144).
The transfer vector (5 μg), the envelope (2 μg), and the
packaging plasmids (5 μg) were co-transfected using cal-
cium phosphate in human embryonic kidney 293 T cells
(6 × 106 cells per dish) cultured in DMEM (Invitrogen,
San Diego, CA) with 10% FCS and 1% penicillin/ strepto-
mycin. Lysosomal function was inhibited with cloroquine
prior to transfection. The supernatant containing the viral
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concentration was titrated by cytometry (FACSAria cyt-
ometer, BD Biosciences, San Diego, CA). Infection effi-
ciency was ~80% as determined using GFP-expressing
viral particles. Frataxin levels were reduced around 50%
compared to scrambled-transfected cells. In a second
method aimed to produce more drastic frataxin deficiency
cells from Lox flanked Fxn transgenic mice were trans-
fected with a Cre recombinase-GFP plasmid using fugene
6 (Roche) or Neurofect (Genlatis) for astrocytes or neu-
rons, respectively. Fugene 6 was used in a 1:3 ratio (DNA:
transfection agent) and Neurofect in a 1:6 ratio. Astrocytes
were used 2 weeks after transfection and neurons were
transfected 1–2 days after plated and used 24 hours later.
Plasmids used were peGFPC1-CRE recombinase or
pCMV-GFP (control). Before stimulation with 100 nM
IGF-I, FBS was removed from the plates. After 24 hours,
cells were processed for Western blot or qPCR. When
inhibitors were used, FBS was removed 3 hours prior to
the addition of the different inhibitors (cycloheximide
1 μg/ml, actinomycin D 2 μg/ml, MG-132 10 μM, rapamy-
cin 100 nM or LY294002 100 μM). Cells were maintained
with the inhibitors for 3 hours before adding IGF-I. Treat-
ments were done in duplicate or triplicate in at least 3 in-
dependent experiments.
Cell assays
Cell viability was assessed in neurons nucleoporated
(Amaxa) with the peGFPC1-CRE recombinase plasmid
and plated over astrocytes. GFP+ neurons were scored
after 24 hours of IGF-I treatment. Neurons were counted
in ten different fields per well at 10×. GFP+ cells were
related to total cell number determined with DAPI nuclear
staining. Cell counts were performed with Metamorph
software using the multi wavelength cell scoring module.
Generation of ROS was assessed with MitoSOXTM Red
reagent from Molecular Probes following the manufac-
turer´s procedure using the cytometer equipped with a
double Argon (488 nm) and Helium-Neon laser (633 nm).
Data were collected by using a linear digital signal process.
The emission filter used was BP 585/42 for MitosoxRed
(FL2). Appropriate values of electronic compensation were
adjusted between fluorescence when needed. Debris and
duplets were always excluded from the analysis. Data were
analyzed with FACSDiva data analysis software (BD
Biosciences) and displayed using bi-exponential scaling.
Mitochondrial activity was measured using a commercial
MTT (3–4,5-dimethylthiazol-2-yl-2,5-dypheniltetrazolium
bromide) assay (Roche Diagnostics, Switzerland) as
described [28]. Assays were done in triplicate dishes.
Production of ROS was also determined by analyzing
H2O2 levels in the cultures as described previously (Brera
et al., 2000), with minor modifications. Briefly, the method
uses the nonfluorescent cell-permeant compound 2′,7′-dichlorofluorescein diacetate (Invitrogen) which can be
oxidized by peroxides to produce the fluorescent com-
pound 2′,7′-dichlorofluorescein. Generation of peroxides
was measured in a FLUOstar plate reader (BMG Lab
technologies, Offenburg, Germany) at an excitation wave-
length of 485 nm and an emission of 520 nm.Immunoassays
Animals were perfused transcardially with saline before
collection of brain samples for biochemical analysis.
Cells or cerebral cortex were homogenized in ice-cold
lysis buffer (1% NP-40, 150 mM NaCl, 20 mM Tris pH
7.4 , 10% glycerol, 1 mM Cl2Ca, 1 mM Cl2 Mg, 400 μM
sodium orthovanadate, 200μM phenyl methylsulfonyl
fluoride (PMSF), 1ug/ml leupeptine, 1ug/ml aprotinin).
Western blot was performed as described [29]. Mem-
branes were re-blotted with β-actin as internal standards
and to normalize for protein load. The ratio of relative
expression was established after subtraction of the back-
ground intensity. Levels of the protein under study were
expressed relative to protein load in each lane. Species-
specific IGF-I ELISA was performed in brain and serum
samples as described [24].Quantitative PCR
Total RNA was extracted from 1.5 × 106 cells using
illustra RNAspin Mini (GE Healthcare). RNA was re-
verse transcribed using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) according to the
manufacturer’s instructions. One μl sample of cDNA
was amplified using TaqMan probes for frataxin
(NM_008044.2) and GAPDH as endogenous control
(Applied Biosystems). Each sample was run in triplicate
for both frataxin and GAPDH in 20 μl reaction using
Taqman Universal PCR Master Mix according to the
manufacturer’s instruction (Applied Biosystems). Reac-
tions were performed in an ABIPrism 7000 sequence de-
tector system. Quantitative real time PCR analysis was
carried out using the 2(−ΔΔC(T)) method (2-ΔΔCt) as
previously described [30]. Results were expressed as rela-
tive expression ratios on the basis of group means for
target frataxin transcript versus reference GAPDH
transcript.Rota-rod test
Motor coordination in mutant mice was assessed with
the rota-rod test as described previously [3] using the
protocol of the authors that developed this mouse [22]
because our former protocol did not detect any ataxia in
these mice (not shown). The protocol consists of 4 trials
of 5 minutes each with a 10 minutes rest between each
trial. No other sensorimotor parameters were measured.
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Statistical analyses were performed with a t test when
comparing two groups and a two-way ANOVA followed
by a t-test when comparing multiple groups. Statistical
significance was established at p<0.05. Results shown are
mean ± SEM.
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